Breaking News, Collaborations & Alliances

Janux Unveils Development Candidate in Bristol Myers Squibb Partnership, Worth $35M Milestone

A tumor-activated therapeutic was identified using Janux’s TRACTr platform.

Author Image

By: Patrick Lavery

Content Marketing Editor

Janux Therapeutics has nominated a development candidate in its collaboration and licensing agreement with Bristol Myers Squibb (BMS). Janux says its TRACTr platform identified a tumor-activated therapeutic targeting an undisclosed solid tumor antigen expressed in multiple cancer types. TRACTr is a backronym standing for ‘Tumor-Activated T-Cell Engager.’ How Janux Will Benefit from Nomination The milestone triggers a $35 million payment to Janux from BMS. The two companies announced the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters